Skip to main content

Advertisement

Table 1 Characteristics of the included studies

From: Systematic review of dengue vaccine efficacy

Author County Design Age (years) Subjects Follow-up time Vaccinated Dengue vaccine* Control Dengue Control**
Villar et al. [10] Colombia, Brazil, Mexico, Honduras and Puerto Rico. ECR phase III 9 to 16 20,869 25 months after the 1st dose 13,920 280 6949 388
Capeding et al. [11] Indonesia, Malaysia, Philippines, Thailand and Vietnam. ECR phase III 2 to 14 10,272 25 months after the 1st dose 6848 286 3424 309
Dayan et al. [12] Brazil ECR phase II 9 to 16 150 6 months after the 3rd dose 100 31 50 15
Villar et al. [13] Colombia, Mexico, Honduras and Puerto Rico. ECR phase II 9 to 16 600 6 months after the 3rd dose 401 43 199 29
Sabchareon et al. [16] Thailand ECR phase IIb 4 to 11 4002 25 months after the 1st dose 2669 76 1333 58
Tran et al. [14] Vietnam ECR phase II 2 to 45 180 6 months after the 3rd dose 120 4 60 3
Lanata et al. [15] Peru ECR phase II 2 to 11 298 1 month after the 3rd dose 199 1 99 3
  1. *Cases of dengue in the vaccinated group
  2. **Cases of dengue in the control group